Random forest prioritizes investigational compounds with antiplasmodial activity
A random-forest classifier screened investigational compounds; after applicability, similarity, diversity, availability and cost filters, six compounds were purchased and tested. CEP-37440 and AZD-1480 had reported P. falciparum IC50 values of 1.22 and 4.00 µM. These are in-vitro findings for existing compounds, not evidence of malaria clinical safety or a confirmed parasite target.
Technology: Random-forest classifier
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary article reports tested CEP-37440/AZD-1480 antiplasmodial activity.
- Still unknown: Selected six are filtered, not a random sample; proposed parasite kinase mechanisms and patient efficacy are unverified.
- AI role: RF ranks investigational compounds from a drug database; human filters determine purchase/assay set.
Evidence sources: https://doi.org/10.1186/s13065-025-01395-4
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: publisher primary full text. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.